PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. has entered into a Letter of Intent to supply its LaNeo MDMA to a clinical trial in exchange for a perpetual license to the resulting efficacy and safety data, a move that underscores the company’s strategic focus on intellectual property. Additionally, PharmAla has settled a $100,000 debt by issuing common shares, reflecting its commitment to financial restructuring and growth.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
